Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.43 |
| ▸ | HRH1 | P35367 | 2/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | LIN28A | Q9H9Z2 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1492627 | 0.83 | HRH1 (0.50) | HRH3HRH1HRH4LMNATAAR1 | |
| SCHEMBL2651595 | 0.79 | CHRM2 (0.51) | L3MBTL1ALDH1A1ALOX15SMN1; SMN2MAOA | |
| SCHEMBL6166087 | 0.77 | L3MBTL1 (0.44) | L3MBTL1HRH3HRH1HRH4LMNA | |
| SCHEMBL15031 | 0.76 | CALM1 (0.32) | — | |
| SCHEMBL41191 | 0.76 | L3MBTL1 (0.59) | L3MBTL1HRH3HRH1HRH4LMNA | |
| SCHEMBL29830938 | 0.76 | L3MBTL1 (0.59) | L3MBTL1HRH3HRH1HRH4LMNA | |
| SCHEMBL6165479 | 0.76 | SMN1; SMN2 (0.44) | L3MBTL1HRH3HRH1HRH4LMNA | |
| Hydrochloric Acid SCHEMBL10884973 | 0.74 | L3MBTL1 (0.57) | L3MBTL1HRH3HRH1HRH4LMNA | |
| Bromide SCHEMBL6114859 | 0.74 | L3MBTL1 (0.57) | L3MBTL1HRH3HRH1HRH4LMNA | |
| SCHEMBL4938201 | 0.74 | L3MBTL1 (0.57) | L3MBTL1HRH3HRH1HRH4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132531-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | GALECTO BIOTECH AB (DK) | 2024-04-25 | — | — | US | claimed |
| EP-4267570-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | Galecto Biotech AB (DK) | 2023-11-01 | — | — | EP | claimed |
| EP-4267568-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | Galecto Biotech AB (DK) | 2023-11-01 | — | — | EP | claimed |
| WO-2023118267-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | GALECTO BIOTECH AB (DK) | 2023-06-29 | — | — | WO | claimed |
| WO-2022144274-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | GALECTO BIOTECH AB (DK) | 2022-07-07 | — | — | WO | claimed |
| WO-2022136365-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | GALECTO BIOTECH AB (DK) | 2022-06-30 | — | — | WO | claimed |
| EP-3994135-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | Galecto Biotech AB (DK) | 2022-05-11 | — | — | EP | claimed |
| US-20220009913-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | BRISTOL MYERS SQUIBB CO (US) | 2022-01-13 | — | — | US | claimed |
| EP-3891144-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | Bristol-Myers Squibb Company (US) | 2021-10-13 | — | — | EP | claimed |
| US-20210147408-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | BRISTOL MYERS SQUIBB CO (US) | 2021-05-20 | — | — | US | claimed |
| WO-2021004940-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | GALECTO BIOTECH AB (DK) | 2021-01-14 | — | — | WO | claimed |
| WO-2020117883-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-06-11 | — | — | WO | claimed |
| WO-2019067702-A9 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-04-25 | — | — | WO | claimed |
| WO-2019067702-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-04-04 | — | — | WO | claimed |
| EP-1056725-B1 | INHIBITION OF RAF KINASE USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS | BAYER PHARMACEUTICALS CORP (US) | 2006-06-07 | — | — | EP | claimed |
| US-20240132531-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | GALECTO BIOTECH AB (DK) | 2024-04-25 | — | — | US | disclosed |
| EP-4267570-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | Galecto Biotech AB (DK) | 2023-11-01 | — | — | EP | disclosed |
| US-4563310-A | HERBICIDES | ZOECON CORPORATION (US) | 1986-01-07 | — | — | US | disclosed |
| US-4563310-A | HERBICIDES | ZOECON CORPORATION (US) | 1986-01-07 | — | — | US | disclosed |
| EP-0065374-A1 | Substituted phosphinates and phosphinothioates and their use for the control of weeds | ZOECON CORPORATION (US) | 1982-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147408-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | LGALS3, LGALS1, LGALS3BP | L3MBTL1 3329/4885HRH3 4534/4885HRH1 4632/4885 |
| US-20240132531-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | LGALS1, LGALS3, LGALS3BP | L3MBTL1 256/4885HRH3 3777/4885HRH1 3294/4885 |
| US-20220009913-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | LGALS3, LGALS1, LGALS3BP | L3MBTL1 3329/4885HRH3 4534/4885HRH1 4632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.